Page 16 - 2020_11-Haematologica-web

Editorials
3. Chakravorthy S. COVID-19 in patients with sickle cell disease – a case series from a UK tertiary hospital. Haematologica. 2020;105(11): 2691-2693.
4. Frater JL, Zini G, d'Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol. 2020;42(1):11-18.
5. Telfer P. Real-time national survey of COVID-19 in hemoglobinopa- thy and rare inherited anemia patients. Haematologica. 2020;105(11):2651-2654.
6. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020;189(5):851-852.
7. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020;95(7):E154-E156.
8. Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso- occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020;95 (6):725-726.
9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting character- istics, comorbidities, and outcomes among 5700 patients hospital- ized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052-2059.
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortal- ity of adult inpatients with COVID-19 in Wuhan, China: a retrospec- tive cohort study. Lancet. 2020;395(10229):1054-1062.
11. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respi- ratory distress syndrome and death in patients with Coronavirus dis- ease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943.
12. Shet AS, Thein SL. A growing population of older adults with sickle cell disease. Clin Geriatr Med. 2019;35(3):349-367.
13. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342(25):1855-1865.
14. Connors JM, Levy JH. Thromboinflammation and the hypercoagula-
bility of COVID-19. J Thromb Haemost. 2020;18(7):1559-1561.
15. (MMWR). CMaMWR. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus di- sease 2019 – COVID-NET, 14 States, March 1-30, 2020. 2020 [cited;
Available from: https://www.cdc.gov/mmwr].
16. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine
or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;S0140- 6736(20):31180-31186.
17. Yazdany J, Kim AHJ. Use of Hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 2020;172(11):754-755.
18. Naymagon L, Berwick S, Kessler A, Lancman G, Gidwani U, Troy K. The emergence of methemoglobinemia amidst the COVID-19 pan- demic. Am J Hematol. 2020;95(8):E196-E197.
19. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387 (10019):661-670.
20. America SCDAo. Sickle cell disease and COVID-19: provider advi- sory. 2020 [cited; Available from: https://www.sicklecelldisease.org /files/sites/181/2020/03/4.10.20-MARAC-SCDAA-PROVIDER- ADVISORY-4-10-2020].
21. DeBaun MR. Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pan- demic. Blood. 2020;135(22):1997-1999.
22. Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Combination dose-escalated hydroxyurea and transfusion: an approach to con- serve blood during the COVID-19 pandemic. Blood. 2020;135(25): 2320-2322.
23. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion sup- port. Blood Adv. 2020;4(2):327-355.
2504
A CD205-directed antibody drug conjugate – lymphoma precision oncology or sophisticated chemotherapy?
Damian T. Rieke1,2 and Ulrich Keller1,3
1Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, 12203 Berlin; 2Berlin Institute of Health (BIH), 10178 Berlin and 3Max-Delbrück-Center for Molecular Medicine, 13092 Berlin, Germany
E-mail: ULRICH KELLER - ulrich.keller@charite.de doi:10.3324/haematol.2020.261073
Precision oncology is expected to improve outcome of patients with malignant diseases by taking into
1
account individual variability. This approach is
strictly linked to the availability of a targeted treatment the efficacy of which depends on the presence of a molec- ular alteration, i.e., a predictive biomarker. This concept has been shown to be highly successful in well-defined subgroups of patients and has led to the histology-agnos- tic approval of drugs in solid tumors.2 Biomarker-stratified treatment has become first-line treatment in several solid tumors, such as non-small cell lung cancer. In many hematopoietic malignancies, including B-cell lymphomas, comparably higher cure rates and more treatment options have led to a more prognosis-oriented stratification of treatment. Here, prognostic biomarkers help to adjust treatment intensity to a cohort risk assessment.3 Together with improved prognostication of patients, a more refined diagnosis also helps with better treatment allocation.
Therefore, diagnostic biomarkers will help with the iden- tification of defined disease subgroups.4 This might also correspond to differential outcome and/or response to treatment, and can therefore overlap with predictive and/or prognostic markers.
However, despite numerous advances in the under- standing of cancer heterogeneity, not all diagnostic or prognostic stratifications will ultimately impact treatment and a number of patients will eventually have disease recurrence or progression. Therefore, the identification of novel treatment strategies is urgently required. The devel- opment of additional predictive biomarkers and corre- sponding drugs promises to improve outcome and limit toxicity. This advancement of precision oncology can be achieved in at least two ways: (i) the identification of the right treatment for given patients (as often tried in umbrel- la or unstratified precision oncology trials);5 or (ii) the identification of the right patient for a given treatment (as
haematologica | 2020; 105(11)